Atlas Molecular Pharma is focused on the discovery of first-in-class, innovative therapeutics for the treatment of patients.
Atlas Molecular Pharma has raised $3.4M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in February 2022.
Atlas Molecular Pharma's investors include Inveready, Kereon Partners, CDTI, Ezten Venture Capital Fund.
Atlas Molecular Pharma is headquartered in Derio, Spain.
Atlas Molecular Pharma is focused on the discovery of first-in-class, innovative therapeutics for the treatment of patients.
Atlas Molecular Pharma is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Atlas Molecular Pharma — Funding & Investors." VCBacked, February 1, 2022, https://www.vcbacked.co/company/atlas-molecular-pharma. Accessed September 29, 2026.
VCBacked. (2022). Atlas Molecular Pharma — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/atlas-molecular-pharma
{{cite web |title=Atlas Molecular Pharma — Funding & Investors |url=https://www.vcbacked.co/company/atlas-molecular-pharma |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated